Boosting osimertinib's reach to the brain
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding febuxostat helps the lung cancer drug osimertinib get into the brain better. It is for people with EGFR-mutated NSCLC who are already taking osimertinib, regardless of whether their cancer is stable or slowly progressing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic EGFR-mutated lung cancer and are currently taking osimertinib.
- Your cancer is stable or your doctor thinks osimertinib is still helpful even if there's some growth.
- You are willing to have extra blood draws and a lumbar puncture (spinal tap).
- You do not have brain metastases (cancer spread to the brain).
- You have not had a genetic test showing the ABCG2 34G>A variant.
- Your overall health is good enough for daily activities (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding cobicistat can increase and stabilize the effect level of osimertinib while keeping treatment cost-effective. You would take osimertinib 80 mg daily, with blood tests to see how your body processes the drug.
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a new combination of two drugs (BL-B01D1 and osimertinib) versus osimertinib alone as the first treatment for people with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better at stopping the cancer from growing.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests a new drug (BL-B01D1) combined with osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and who have not had any previous treatment. The goal is to see if the combination works better than standard care.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.